Cb therapeutics and atai life sciences launch tryptagenix to sustainably supply and develop clinically relevant compounds to tackle the growing mental health crisis

Tryptagenix will research and develop new sustainable methods of manufacturing therapeutic compounds commercially with increased reproducibility and reliability for clinical use. this partnership will also leverage cb therapeutics' versatile platform to propel the development of new chemical entities for next-generation mental health treatments tryptagenix will research and develop new sustainable methods of manufacturing therapeutic compounds commercially with increased reproducibility and reliability for clinical use. this partnership will also leverage cb therapeutics' versatile platform to propel the development of new chemical entities for next-generation mental health treatments
ATAI Ratings Summary
ATAI Quant Ranking